A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF)
Clinical Trial Grant
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
Boehringer Ingelheim Pharmaceuticals, Inc.
Start Date
March 22, 2023
End Date
August 25, 2027
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
Boehringer Ingelheim Pharmaceuticals, Inc.
Start Date
March 22, 2023
End Date
August 25, 2027